LUND, Sweden, May 4, 2021 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") announced today that the following members of the Board of Directors have purchased shares in the company:

   

Member

  

Number of Shares

 

Total Investment                                   

                                   

Peter Høngaard Andersen

 

1,500

 

171,000 SEK                                        

                                   

Hans Johansson

 

1,700

 

192,100 SEK                                             

                                   

TOTAL

 

3,200

 

363,100 SEK                            

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. The final validation study was completed in Q1 2021. The accreditation process for Immunovia Inc. in Marlborough, Massachusetts, USA is ongoing and commercial testing will begin in Q2 after the accreditation. The European launch plan will be communicated Q2 2021.

IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. The test will be exclusively provided by Immunovia Inc., Marlborough, Massachusetts, USA.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

CONTACT:

For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/members-of-immunovia-s-board-of-directors-purchase-shares-in-the-company,c3340062

The following files are available for download:

https://mb.cision.com/Main/13121/3340062/1412517.pdf

Press release (PDF)

 

Copyright 2021 PR Newswire

Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022 Haga Click aquí para más Gráficas Immunovia Ab (publ).
Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022 Haga Click aquí para más Gráficas Immunovia Ab (publ).